Levels of methylenetetrahydrofolate in Krebs ascites cells subsequent to transplantation and the effects of methotrexate on these levels have been measured. To directly measure methylenetetrahydrofolate in tissue extracts, the cofactor was incorporated into a covalent ternary complex with thymidylate synthase and 3H-labelled fluorodeoxyuridine monophosphate. A 3-4-day lag preceded rapid growth of the tumour cells, and this same kinetic behaviour was observed for methylenetetrahydrofolate levels in the tumour cells. Liver and kidney tissue from the same animals also showed an increase in methylenetetrahydrofolate over the same time period. The impact of methotrexate on methylenetetrahydrofolate in the tumour cells depended upon concentration and the post-transplantation time at which treatment was initiated. Levels of methylenetetrahydrofolate in the tumour cells were most sensitive to the drug at the beginni-ng of the rapid growth phase and were more sensitive to a given level of methotrexate in the presence of phospholipids. A slight but significant increase in methylenetetrahydrofolate occurred in some cases in response to the presence of methotrexate.
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The antifolate methotrexate has been effective in the treatment of a number of neoplasms (Johns & Bertino, 1973; Chabner et al., 1975) and has been shown to have a high affinity for the enzyme dihydrofolate reductase (Bertino et al., 1965 (Blakely, 1967; Hunnekens et al., 1976; Goldman, 1977; Danenberg, 1977) .
Ascites tumour cells grown intraperitoneally are also anticipated to respond to methotrexate through a decrease in methylenetetrahydrofolate, resulting from inhibition of dihydrofolate reductase (White & Goldman, 1981 Vol. 216 in groups of six and fed standard lab chow and water ad libitum. Tumour weight was determined from the difference between the weight of inoculated and tumour-free control mice.
Methylenetetrahydrofolate was determined as described previously (Priest et al., 1982 (Priest et al., , 1983 Bradford (1976) .
Liposomes were prepared by evaporation to dryness of a lOml chloroform solution that contained 30mg of egg phosphatidylcholine, 4.4mg of cholesterol and 1.6mg of stearylamine. The dried lipid film was removed, and liposomes were formed with 10 ml of 0.15 M-NaCl and agitation on a vortexmixer under an N2 atmosphere. To prepare drugentrhpped liposomes, the dried lipid film was removed with lOml of methotrexate (6.0mg/ml) dissolved in 0.15 M-NaCl.
Results
Fig . 1 shows the change in methylenetetrahydrofolate levels in liver, kidney and tumour cells of mice after intraperitoneal inoculation with Krebs ascites cells. Growth of tumour cells over the same period is also shown. It can be seen that a lag in the growth rate of the ascites cells occurs initially, with maximal growth occurring after day 4, as has been observed previously with Ehrlich ascites cells (Eckhardt et al., 1982) . This rapid phase of growth occurs concomitantly with an increase in the methylenetetrahydrofolate level of the tumour cells and two major organs of the mouse as well. As the growth rate slows and host death approaches, methylenetetrahydrofolate in liver, kidney and the tumour cells returns to near baseline levels. Fig. 2 shows that the concentration of methylenetetrahydrofolate responds to the presence of methotrexate 24h after administration. The cofactor level is diminished in a strict dose-dependent manner if the drug is administered on day 4 after transplantation but not on day 8. Also, the cells are more drug-sensitive on day 4 compared with day 8. In fact a slight increase in cofactor level results from low drug levels at the latter post-transplantation An attempt was made to use liposomal encapsulation of methotrexate to gain a more rapid uptake and therefore obtain a more rapid response to the drug (Gregoriadis, 1978) . Fig. 4 shows that liposomal preparations enhanced the response observed with methotrexate. However, approximately the same decrease in methylenetetrahydrofolate was observed regardless of whether methotrexate had been encapsulated into liposomes or simply administered in the presence of phospholipid. Thus, methotrexate in the presence of lipid had a greater impact on lowering methylenetetrahydrofolate levels than in the absence of lipid, but uptake enhancement was probably not due to liposomal encapsulation of the drug.
Discussion
In order to replicate, ascites cells grown intraperitoneally must acquire folate from the host. This folate may already be in a usable reduced form or could be metabolized to such a form after uptake. This acquisition, at least with regard to methylenetetrahydrofolate, does not occur immediately Time (h) Fig. 3 upon transplantation (see Fig. 1 ). A lag of several days precedes an increase in the intracellular level of this cofactor form. A similar lag precedes rapid growth of the tumour mass. Since many other events are also required for tumour growth, it cannot be concluded that the lag is due to an inadequate supply of methylenetetrahydrofolate alone, but it is possible that this is at least one of the contributing factors to the delay in attainment of a rapid growth rate.
Since the only source of folate to support tumour cell growth is the host animal, levels of cofactor in selected mouse tissues were examined in the present study. Rather than depletion of host methylenetetrahydrofolate pools in the liver and kidney, as had been expected, the presence of the tumour caused an increase in this cofactor form in both tissues. Since there was no change in dietary availability of folate to these animals, it is probable that the presence of the tumour cells resulted in a diversion from the total folate pool into the methylenetetrahydrofolate form to support the rapid growth of the tumour cells. This could suggest that reduced folates are available to tumour cells for uptake and utilization without extensive metabolism. However, it is also possible that the same circulating factor(s) is capable of diverting tumour-cell, as well as liver and kidney, folates into the methylenetetrahydrofolate form.
The methylenetetrahydrofolate level in tumour cells responded to the antifolate, methotrexate. The greater sensitivity during the early stages of growth could possibly be related to lower intracellular levels of methylenetetrahydrofolate at this time. During later stages there is a higher concentration of methylenetetrahydrofolate and cells have passed the point of maximum growth. At this later stage other factors may become limiting, and thus reliance on methylenetetrahydrofolate is diminished.
The initial effect of methotrexate in these cells is an increase in the methylenetetrahydrofolate level. This effect diminishes with post-inoculation age of the tumour cells. Such a methotrexate-caused increase is in direct contradiction to the presumed primary effect of this antifolate (i.e. inhibition of dihydrofolate reductase resulting in decreased methylenetetrahydrofolate). The mechanism by which this apparent initial enhancement occurs is unclear and requires further investigation in the future.
